undamentalytics Newsletter
Sign in

Enanta Pharmaceuticals Inc balance sheet

At the end of fiscal 2025, Enanta Pharmaceuticals Inc had total assets of $281m, total liabilities of $216m and shareholders' equity of $64.7m. It held $32.3m in cash against $0 of debt: net cash of $32.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Cash and equivalents711931221766645187574485373233
Receivables—11215131167512324209777
Total current assets—47105108171232238380402437319312423300204204
Total assets—52117155246281327414490486439375462377281297
Accounts payable—2122345761064823
Deferred revenue (current)—00—————————————
Total current liabilities—6557821162324363063584954
Total debt0000000000000000
Total liabilities—8771011252127313954246248216196
Shareholders' equity−132−11511014923627030239446245639932121712965101
Non-controlling interests and other (assets − liabilities − equity)—159——————————————
Net debt (negative = net cash)−7−11−9−31−22−17−66−64−51−87−57−44−85−37−32−33
Shares outstanding——18m19m19m19m19m19m20m20m20m21m21m21m21m29m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABCL vs ENTACUVL vs ENTACYTK vs ENTA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Enanta Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Enanta Pharmaceuticals Inc.